Pyxis Oncology
PYXS
About: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Employees: 44
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
700% more call options, than puts
Call options by funds: $16K | Put options by funds: $2K
2% more capital invested
Capital invested by funds: $29.6M [Q1] → $30.2M (+$571K) [Q2]
4.78% less ownership
Funds ownership: 49.11% [Q1] → 44.33% (-4.78%) [Q2]
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
16% less funds holding
Funds holding: 88 [Q1] → 74 (-14) [Q2]
48% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Guggenheim
Brad Canino
|
$5
|
Buy
Initiated
|
4 Sep 2025 |
|
HC Wainwright & Co.
Swayampakula Ramakanth
|
$5
|
Buy
Reiterated
|
19 Aug 2025 |
Financial journalist opinion
Based on 3 articles about PYXS published over the past 30 days
